Stockscreener 앱 받기
1.08
3.57%
-0.04
시간 외 거래:
1.10
0.02
+1.85%
전일 마감가:
$1.12
열려 있는:
$1.11
하루 거래량:
2.81M
Relative Volume:
0.69
시가총액:
$392.23M
수익:
$1.21M
순이익/손실:
$-177.12M
주가수익비율:
-1.35
EPS:
-0.8
순현금흐름:
$-162.37M
1주 성능:
+0.93%
1개월 성능:
+17.83%
6개월 성능:
+51.37%
1년 성능:
-35.71%
1일 변동 폭
$1.04
$1.15
1주일 범위
$1.03
$1.27
52주 변동 폭
$0.2836
$2.175
렉시콘 파마슈티컬스 Stock (LXRX) Company Profile
명칭
Lexicon Pharmaceuticals Inc
전화
(281) 863-3000
주소
2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS
LXRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LXRX
Lexicon Pharmaceuticals Inc
|
1.08 | 417.65M | 1.21M | -177.12M | -162.37M | -0.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
렉시콘 파마슈티컬스 Stock (LXRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-05 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-06-17 | 개시 | H.C. Wainwright | Buy |
| 2024-04-30 | 개시 | Leerink Partners | Outperform |
| 2023-03-07 | 개시 | Jefferies | Hold |
| 2022-08-12 | 개시 | Piper Sandler | Overweight |
| 2021-01-29 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2021-01-29 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2020-12-08 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-11-18 | 업그레이드 | Gabelli & Co | Hold → Buy |
| 2019-12-11 | 다운그레이드 | Gabelli & Co | Buy → Hold |
| 2019-11-08 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2019-09-11 | 업그레이드 | Gabelli & Co | Hold → Buy |
| 2019-07-29 | 다운그레이드 | Stifel | Buy → Hold |
| 2019-03-25 | 업그레이드 | Gabelli & Co | Sell → Hold |
| 2018-07-31 | 재확인 | Stifel | Buy |
| 2018-02-23 | 다운그레이드 | Needham | Buy → Hold |
| 2018-02-14 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2017-03-01 | 재확인 | H.C. Wainwright | Buy |
| 2017-03-01 | 재확인 | Wedbush | Outperform |
| 2016-10-07 | 개시 | H.C. Wainwright | Buy |
| 2016-08-05 | 재확인 | Wedbush | Outperform |
| 2016-08-02 | 개시 | Citigroup | Buy |
| 2016-03-02 | 재확인 | Wedbush | Outperform |
| 2015-11-09 | 재확인 | Wedbush | Outperform |
| 2015-09-28 | 업그레이드 | Gabelli & Co | Sell → Hold |
| 2015-09-18 | 다운그레이드 | Gabelli & Co | Hold → Sell |
| 2015-08-10 | 다운그레이드 | JP Morgan | Overweight → Neutral |
모두보기
렉시콘 파마슈티컬스 주식(LXRX)의 최신 뉴스
Trendline Breach Raises Concern for Lexicon Pharmaceuticals Inc. InvestorsWeekly Return Pick Forecast Reports Show Trend - metal.it
Citigroup Boosts Lexicon Pharmaceuticals Price Target, Maintains 'Buy' Rating. - AInvest
Lexicon Pharmaceuticals Advances Study on Sotagliflozin for Hypertrophic Cardiomyopathy - TipRanks
Lexicon (LXRX) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Balanced Outlook for Lexicon Pharmaceuticals Amid Strategic Gains and Revenue Challenges - TipRanks
Citigroup Raises Lexicon Pharmaceuticals PT to $1.9, Maintains Buy Rating - AInvest
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q2 2025 Earnings Call Transcript - Insider Monkey
Lexicon Pharmaceuticals 2025 Q2 Earnings Remarkable Turnaround with 106.1% Net Income Increase - AInvest
Lexicon: Q2 Earnings Snapshot - Greenwich Time
Lexicon Pharmaceuticals Reports Strong Q2 2025 Results - TipRanks
Jefferies raises Lexicon Pharmaceuticals stock price target to $0.85 By Investing.com - Investing.com Australia
Jefferies raises Lexicon Pharmaceuticals stock price target to $0.85 - Investing.com
Lexicon Pharmaceuticals’ Q2 2025: Navigating Contradictions in Trial Designs, Partnering Strategies, and Financial Guidance - AInvest
Lexicon Pharmaceuticals, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:LXRX) - Seeking Alpha
Lexicon Pharmaceuticals Reports Surprising Q2 Earnings and RevenueNews and Statistics - IndexBox
Lexicon Pharmaceuticals (LXRX) Q2 Earnings and Revenues Top Estimates - sharewise.com
LEXICON PHARMACEUTICALS Earnings Results: $LXRX Reports Quarterly Earnings - Quiver Quantitative
Lexicon Pharmaceuticals Inc (LXRX) Reports Q2 2025 Earnings: EPS - GuruFocus
Lexicon Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates - The Manila Times
Lexicon Pharmaceuticals reports Q2 results, Phase 2b PROGRESS study results, and Q3 enrollment target. - AInvest
Evaluating Lexicon Pharmaceuticals' Q2 2025 Earnings and Institutional Investor Sentiment: A Path to Value Creation Amid Mixed Analyst Ratings - AInvest
Published on: 2025-08-04 19:08:28 - metal.it
H.C. Wainwright Reiterates a Buy Rating on Lexicon Pharmaceuticals (LXRX) - MSN
Is Lexicon Pharmaceuticals Inc. stock overvalued or undervaluedBuild a winning investment strategy - Jammu Links News
Published on: 2025-08-04 02:57:12 - Jammu Links News
What is the risk reward ratio of investing in Lexicon Pharmaceuticals Inc. stockMarket-beating performance - Jammu Links News
What are Lexicon Pharmaceuticals Inc. company’s key revenue driversUnstoppable profit momentum - Jammu Links News
What makes Lexicon Pharmaceuticals Inc. stock price move sharplyBuild a diversified portfolio for risk management - Jammu Links News
What are analysts’ price targets for Lexicon Pharmaceuticals Inc. in the next 12 monthsInvest smarter with real-time trading signals - Jammu Links News
What is the dividend policy of Lexicon Pharmaceuticals Inc. stockConsistent triple returns - Jammu Links News
Does Lexicon Pharmaceuticals Inc. stock perform well during market downturnsGet timely alerts on market movers - Jammu Links News
Should I hold or sell Lexicon Pharmaceuticals Inc. stock in 2025Tap into rapid wealth building techniques - Jammu Links News
Is Lexicon Pharmaceuticals Inc. a good long term investmentUnstoppable trading performance - Jammu Links News
How does Lexicon Pharmaceuticals Inc. generate profit in a changing economyMaximize portfolio value with smart investment plans - Jammu Links News
What drives Lexicon Pharmaceuticals Inc. stock priceSky-high profits - Jammu Links News
How volatile is Lexicon Pharmaceuticals Inc. stock compared to the marketCapitalize on momentum-driven stocks - Jammu Links News
Is Lexicon Pharmaceuticals Inc. a growth stock or a value stockBuild a portfolio with strong long-term growth - Jammu Links News
How does Lexicon Pharmaceuticals Inc. compare to its industry peersPre Market Forecasts For Smart Trading - Jammu Links News
Why Lexicon Pharmaceuticals Inc. stock attracts strong analyst attentionLow Risk Swing Trade Opportunities Identified - metal.it
Will Lexicon Pharmaceuticals Inc. continue its uptrendRisk Controlled Picks With Real Returns Outlined - metal.it
Lexicon Pharmaceuticals regains Nasdaq compliance - Investing.com Australia
Lexicon Pharmaceuticals Regains Nasdaq Compliance with Bid Price Requirement - AInvest
Lexicon Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement - The Manila Times
Lexicon Pharmaceuticals regains Nasdaq compliance By Investing.com - Investing.com UK
How sentiment analysis helps forecast Lexicon Pharmaceuticals Inc.Capital Protection Trading Strategies Gain Interest - metal.it
Technical Charts Suggest Momentum Shift in Lexicon Pharmaceuticals Inc.High Return Stock Focus With Safety Emphasized - metal.it
Lexicon Pharmaceuticals Meets Nasdaq Bid Price Requirement, Boosting Market Position - AInvest
Why is Lexicon Pharmaceuticals Inc. stock attracting strong analyst attentionExpert Picks Guidance For 2025 - jammulinksnews.com
How strong is Lexicon Pharmaceuticals Inc. company’s balance sheetDynamic investment growth - jammulinksnews.com
렉시콘 파마슈티컬스 (LXRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):